Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 13/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111164 | 0.80 | LMNA (0.47) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL6111154 | 0.78 | SLC1A3 (0.36) | LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL6103223 | 0.77 | SMN1; SMN2 (0.44) | LMNASMN1; SMN2ACHEHTTTGM2 | |
| SCHEMBL6615188 | 0.72 | TOP2A (0.40) | LMNASMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL7289871 | 0.72 | SMN1; SMN2 (0.78) | LMNASMN1; SMN2HTTTGM2ALDH1A1 | |
| SCHEMBL6786447 | 0.72 | — | — | |
| SCHEMBL6645232 | 0.71 | HTT (0.67) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL24990083 | 0.70 | TGM2 (0.65) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL19957878 | 0.70 | TGM2 (0.65) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL7287265 | 0.69 | LMNA (0.52) | LMNASMN1; SMN2HTTALDH1A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | LMNA 574/4885SMN1; SMN2 2007/4885ACHE 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.